Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b by unknown
PURIFICATION  AND  CHARACTERIZATION  OF  A 
MEMBRANE  PROTEIN  (gp45-70)  THAT  IS  A  COFACTOR 
FOR  CLEAVAGE  OF  C3b  AND  C4b 
BY  TSUKASA SEYA, JERRY  R. TURNER,  AND JOHN P. ATKINSON 
From the Howard Hughes Medical Institute Laboratories and the Department of Medicine, 
Division of Rheumatology, Washington University School of Medicine, 
St. Louis, Missouri 63110 
C4b and C3b are components of the membrane-bound and fluid-phase C3 
convertases, C4bC2a and C3bBb (1), and these bimolecular complexes cleave C3 
to C3a and C3b (2, 3). Complement regulatory proteins limit the activity of C4b 
and/or C3b,  reversibly, by accelerating the decay of the C3 convertases (4-7) 
or, irreversibly, by acting as a cofactor for I-dependent cleavage (4-6,  8). Two 
plasma  proteins,  H  and  C4b-binding  protein  (C4bp),  and  two  cell-associated 
molecules, C3b/C4b receptor (CR 1) and decay-accelerating factor (DAF), l have 
been identified with such regulatory activity. 
Our laboratory has reported that  three distinct proteins are isolated by C3 
affinity chromatography (9).  One of these has been identified as the C3b/C4b 
receptor or CR1  (Mr ~200,000), and a second as the C3d receptor or CR2 (Mr 
140,000).  However,  the third  one,  termed gp45-70  because of its  relatively 
broad  bands  and  cell-specific variations  in  Mr  on  SDS-PAGE,  has  not  been 
purified or functionally characterized. This protein is present on human platelets 
(10), monocytes, and B and T  lymphocytes, but not on erythrocytes (8). Though 
there is no unequivocal evidence that gp45-70 of each cell population is related, 
these proteins show similar Mr,  with one or two broad  bands on  SDS-PAGE, 
binding  specificity for  C3b  but  not  C3d,  and  similar  alterations  in  Mr  with 
reduction  or  enzymatic digestions  with  deglycosidases (9,  11).  C3b  binding 
proteins of similar Mr have been reported on rabbit macrophages (12,  ! 3), and 
more recently on mouse leukocytes (14, 15). Their relationship to human gp45- 
70, except for a similar Mr and ligand-binding specificity, is unknown. 
Preliminary functional studies (16) of gp45-70 indicated that this protein is a 
cofactor for  I-dependent cleavage of C3b.  We  have purified a  protein  from 
several human cell lines that is a cofactor for I-dependent cleavage of C3b, and 
we show that it is identical to gp45-70. 
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Materials and  Methods 
Complement Components.  Human CIs (17), C4 (18), C2 (19), D (20), and B (21) were 
purified as described. These components were assessed by gel criteria for purity and by 
fluid-phase classical  and alternative pathway assay systems to be certain that they were 
free of H, C4bp, and C3 (22).  C3 was purified as previously described (8).  In the assays 
of cofactor activity of I-mediated cleavage, C3 was further purified by passage through a 
column of anti-H antibody conjugated to Sepharose and rechromatography on DEAE- 
Sephacel to eliminate C4bp (22). C3(H20) and methylamine (MA)-treated C3 (C3MA) were 
prepared as previously noted  (22).  C3(HzO)  and  C3MA are  hemolytically inactive C3 
produced  by  repetitive  freeze-thaw  cycles  and  MA  treatment,  respectively.  C4MA is 
hemolytically inactive C4 produced by MA treatment. The conversion of C3 to C3(H~O) 
was confirmed by the heat-induced autocleavage reaction (23). Human I (24), C4bp (25), 
and H  (26) were purified as described.  H  was depleted of C3 by rechromatography on 
QAE-Sephadex. C4bp contained no detectable C3 or H as assessed by radioimmunoassay 
(22).  All of these components were dialyzed against PBS, pH 7.2, and stored in aliquots 
at -70 °C. 
Solubilization and Purification of Cofactor Protein from U937.  The human monocytic 
cell line U937 was cultured at 37°C in a 0.5% COs atmosphere in RPMI 1640 with 2 mg 
glutamine and  10%  FCS and antibacterial/mycotic mixture (Gibco Laboratories, Grand 
Island, NY). The culture media was doubled every other day, and 1-3 x  101° cells were 
harvested from 20 liters of the media. The media was removed by centrifugation (1,300 
g for 8 rain). The packed cells (-20 ml) were washed five times with 3 liters of PBS, and 
finally once with PBS containing 10 mM EDTA, 10 mM iodoacetamide (IAA), and 2 mM 
PMSF. The washed cells were solubilized by 100 ml of PBS (pH 8.0) containing  10 mM 
EDTA,  10 mM IAA, 2 mM PMSF, and  1% NP-40. The mixture was allowed to stir for 
1 h at room temperature. The solubilized preparation was then centrifuged (4,800 g for 
10 min) at 4°C, and the supernatant was collected, dialyzed against 20 mM acetate buffer 
with 0.1%  N P-40, pH 5.0,  overnight at 4°C, and stored at -70°C.  Solubilization of a 
human T-cell line, HSB-2, was performed by the same procedure. 
The first section of the Results, Table I, and the two subsequent paragraphs present 
data on the purification of a cell-associated protein with cofactor activity. Problems that 
were encountered, alternative chromatographic procedures evaluated, and the purifica- 
tion procedure that was finally used are noted below. 
A confounding problem was that the protein was found to stick irreversibly to various 
surfaces, such as membrane filters for ultra-filtration, and chromatographic media. Con- 
centration of the protein using a Diaflo or Centriflo membrane filters resulted in loss of 
the cofactor activity. The recovery of the cofactor activity from DEAE-Sephacel (cellulose) 
or protein conjugated to Sepharose (agarose) was <10 and ~70%, respectively. A similar 
loss of protein was reported in the purification of C4bp (18). >80% of the cofactor protein 
also  bound  to  heparin-Sepharose,  which  has  been  used  to  purify  other  complement 
regulatory proteins (18, 22, 26). However, the recovery of cofactor protein from heparin- 
Sepharose was only ~50%, and therefore this column was not used.  Satisfactory yields 
and purity were obtained using the four columns as described in the next paragraph. 
The  starting  material was  ~3  ×  101° NP-40-solubilized cells.  This preparation was 
dialyzed against 20 mM acetate buffer with 0.1% NP-40, pH 5.0, and the precipitate was 
removed by centrifugation. The supernatant (~300 ml) was applied to a chromatofocusing 
column (2.0 x  50 cm). The equilibration buffer was 20 mM acetate with 0.05% NP-40, 
pH 4.75. The column was washed with the same buffer and then eluted with a linear (20- 
250 raM) gradient of acetate buffer (pH 4.3) in 10% (vol/vol) poly buffer 74. The fractions 
containing cofactor activity (Fig.  1) were pooled after dialysis against  10 mM Tris-HCl 
plus 0.05%  NP-40, pH 7.5. The dialyzed material was loaded on a hydroxylapatite (50 
ml, high resolution; Calbiochem-Behring Corp., LaJolla, CA). The equilibration and wash 
buffer was  15 mM Tris-HCl containing 0.05%  NP-40, pH 7.5.  This column was eluted 
with  15  mM phosphate and 0.05%  NP-40, pH 7.5, and fractions with cofactor activity 
were pooled. The pooled fractions were loaded on a C3MA-Sepharose  (50 ml) column. 
The equilibration buffer was 10 mM phosphate with 0.05% NP-40, pH 7.2, and the wash SEYA ET  AL.  839 
buffer was 20 mM phosphate with  1 mM PMSF and 0.05% NP-40, pH 7.0. The column 
was eluted  with  0.5  M  NaCI and  20 mM phosphate with  0.05%  NP-40, pH  7.0.  The 
fractions with cofactor activity were pooled and dialyzed against 20 mM NaCI and 20 mM 
phosphate with 0.05% NP-40, pH 7.0. The dialyzed material was loaded onto a Mono Q 
column. The equilibration  and  wash  buffer was  20  mM  NaC! and  20  mM  phosphate 
buffer containing 0.05% NP-40, pH 7.0. This column was eluted with a linear gradient 
of 20-500 mM NaCI in the same buffer as used for equilibration.  The flow rate was  1 
ml/min and 2-ml fractions were collected. It required -90 min to complete the gradient 
(see Fig. 2). Except for the chromatofocusing step, which was performed at 4°C, column 
work was carried out at room temperature. 
Determination of Cofactor Activity for 1-mediated C3Ma and C4Ma Cleavage.  MA-treated 
and  N-(dimethylamino-4-methyl coumarinyl)  maleimide  (DACM)-labeled  C3  (DACM- 
C3MA) was prepared as a  substrate  for I as described (27).  Briefly,  10 mg of C3MA was 
mixed with 10 #1 of 2 mg DACM per milliter acetone. The mixture was allowed to stand 
for 15 min at room temperature (22,  26).  MA-treated and DACM-labeled C4,  DACM- 
C4MA, was prepared by the same method. If DACM-C3MA was to be also labeled by l~I, 
the sample was mixed with Na~5I in the iodogen-coated glass tube for 30 min at room 
temperature.  The labeled substrate was dialyzed against PBS and stored in aliquots at 
-70°C. 
5-20 #g of substrate (usually  18 #g of DACM-C3uA in  10 #l) was mixed with 1 #g of I 
and  100  #1 of each column fraction that had been  dialyzed against  20 mM phosphate 
buffer plus 0.05% NP-40, pH 7.2, or PBS plus 0.05% NP-40, pH 7.2. The mixtures were 
incubated for 3-10 h and subjected to SDS-PAGE (10% rod gels) (28) after the addition 
of 30 #i of a 30%  2-MER and 1% SDS solution. Modifications of this protocol were used 
in experiments to compare the cofactor activity of the various regulatory proteins (legends 
to Figs. 5-7). Cofactor activity was monitored by depletion of the fluorescent labeled a 
chain of C3MA and accumulation of a fluorescent labeled c~ chain (27).  Percent cleavage 
was calculated from the fluorescent intensity at  Em/Ex  =  375/485  nm, or by gamma 
counting of the  gel  slices as  previously described  (26,  27).  In experiments  comparing 
cofactor activity of proteins,  1 U of activity represents the quantity of cofactor required 
for cleavage of 1 #g of C3MA per hour under the incubation conditions outlined in the 
figure legend. 
Protein Concentration.  In the absence of NP-40, protein concentration was determined 
by the absorbance at 280 nm, assuming an absorption coefficient value of one for a  1-cm 
cuvette at 280 nm for a 0. 1% solution. Protein concentration of fractions containing NP- 
40 was determined by the method of Kumar et ai.  (29) as previously noted (22),  or by 
estimating the difference of the absorbance at 280 nm between sample fractions and the 
control buffer, which contained the same amount of NP-40. 
Labeling of Cofactor Protein.  Purified protein and each partially purified fraction were 
labeled by the iodogen method, according to the manufacturer's booklet.  If necessary, 
free  125I was  removed  by  gel  filtration  using  Sephadex  G-75.  Surface  labeling  was 
performed by a modified method using lactoperoxidase (30,  31). 
Isolation of Surface-labeled gp45-70.  One-step affinity chromatography was performed 
using C3(H20)-Sepharose. The details  of this procedure are given by Cole et al. (9) and 
Dykman et al. (30).  Briefly,  after passing the surface-labeled solubilized  sample (0.15 M 
NaCI plus 1% NP-40, pH 7.4) through IgG-Sepharose, the sample was diluted three times 
with distilled  water. The diluted sample was mixed with C3(H20)-Sepharose, which had 
been  equilibrated  with  three  times-diluted  PBS containing 0.3%  NP-40,  pH  7.4,  and 
agitated  for 2  h  at  room temperature.  The  mixture  was  then  packed in  the  column, 
washed with  the equilibration  buffer, and eluted with 0.4  M NaCI,  1%  NP-40, and 20 
mM phosphate buffer, pH 7.4. 
Autoradiography.  Autoradiography was performed with XAR-5 film (Eastman Kodak, 
Rocbester,  NY) and  Cronex intensification  screens (Dupont,  Wilmington, DE)  (9,  30). 
The gels were dried and exposed at -70°C for 2 d in the case of surface-labeled materials, 
or for 2 h in the case of purified samples. 
Determination  of Decay-accelerating Activity for  Classical and  Alternative  C3  Conver- 840  MEMBRANE PROTEIN  WITH COFACTOR  ACTIVITY 
TABLE  I 
Purification of a Cofactor Protein ofU937 
Cofactor  Purification 
Purification method  Total protein  activity*  Recovery  (fold) 
Visualiza- 
tion of 
band in 
SDS-PAGE* 
mg  U  % 
Solubilized preparation  5,823  1,193  100  1 
Supernatant of acid and low  180  1,039  87  28 
ionic strength precipitation 
Chromatofocusing  21  978  82  233 
Hydroxylapatite  3  955  80  1,646 
C3MA-Sepharose  (0.1)  0  692  58  33,773 
Mono Q  (0.02)  668  (56)  163,044 
These data are derived from a  purification in which 3  x  101° cells were used,  and the data are 
representative of four such purifications. 
* Cofactor activity at each step was estimated as described in Materials and Methods.  1U is defined 
as the cofactor activity" (fluorescent method) required for cleavage of 1 ~g of C3MA per hour under 
the above conditions. Small amounts of CR1  would be present in the solubilized preparation and 
in the supernatant of the acid and low salt precipitation step. CR1  is eliminated at the chromato- 
focusing step, 
* Fractions run on gels were assessed by protein staining or labeling (see Materials and Methods). 
0 Numbers in parentheses represent the sum of the protein or cofactor activity (fluorescent method) 
determined by adding the amount of activity in each fraction. 
tases.  Fluid-phase assay systems were used (22).  The buffer used was PBS with 0.05% 
NP-40, pH 7.2. For determination of inhibitory activity of the alternative C3 convertase, 
20 ~1 of a solution containing variable (0.1-0.5 pmol) amounts of C3(H~O), 20 pmol of 
B, variable (20-100 pmol) amounts of C3, and 50 nmol of NiCI~ was mixed with  100 ul 
(200 ng) of cofactor protein. After a 2-min incubation at 37 ° C, the reaction was initiated 
by  adding  0.2  ug  of  D.  H  (200  ng)  was  used  as  a  positive  inhibitory  control.  For 
determination  of inhibitory  activity  of the  classical  C3  convertase,  15  ~1  of solution 
containing 0.1-0.5 pmol of C4,  10 pmol of C2, 40 pmol of C3, and  100 ~mol of MgCI2 
was mixed with  100 #1 (200 ng) of cofactor protein or C4bp. CIs (0.1  ~g) was added to 
initiate the reaction in the same manner as for the alternative pathway. 
At  timed  intervals,  50  #1  samples  were  withdrawn  and  mixed  with  50  IA  of the 
precipitating reagent (Upjohn  Diagnostics,  Kalamazoo, MI) and  20 tA of BSA solution 
containing 100 mg BSA per milliliter PBS. The samples were then centrifuged at 12,000 
rpm (Microfuge  12;  Beckman Instruments, Inc., Fullerton, CA) for 5 min at 4°C.  The 
aliquots of the supernatants were transferred to the tubes to be used in the RIA. The 
assay procedure for determination of the released C3a was according to instructions in 
the kit (812-321-0021 ; Upjohn). 
Results 
Purification of Cofactor Protein.  A  purification  procedure  was devised based 
on  our  recent  experience  with  a  multiple  column  method  for  the  isolation  of 
CR1  (22),  the  acidic  pI  of gp45-70  (11),  the  iC3  and  C3b  ligand  affinity of 
gp45-70  (9), and preliminary evidence suggesting that solubilized preparations 
of  U937  possessed  cofactor  activity  (16).  The  purification  was  followed  by 
assessing cofactor activity of column  eluates and/or Mr of radiolabeled  eluates 
on  autoradiographs  of  SDS-PAGE.  The  details  of  the  final  procedure  are 
presented in Materials and Methods and Table I, and outlined below. 
Supernatant  (~300  ml) from solubilized  U937  cells (~3  ×  101°),  containing SEYA ET  AL.  841 
FmuR~  I.  Elution  profile of the chromatofocusing column. The protein concentration was 
determined  by assessing the absorption  of the fractions at 280  nm.  For determination  of 
cofactor activity, 5 #g of DACM-C3MA was incubated for 6 h at 37°C with 1 #g of I and 100 
#1 of each fraction,  which had been dialyzed against PBS and 0.05% NP-40. Aliquots were 
electrophoresed  on SDS-PAGE (10% acrylamide) and the degree of cleavage of the a chain 
into al  fragment was monitored  by measuring the fluorescent intensity (inset electrophore- 
togram) (27). Percent cleavage was calculated from the fol{owing  formula: F(otl)/[F(a) + F(at)] 
where F(a) and F(al) are the fluorescent intensities of a and ~tl band, respectively. 
5,823  mg of protein  was  centrifuged  (31,000  g  for  20  min)  at  4°C,  and  the 
supernatant  was collected.  The supernatant,  containing  ! 80  mg of protein,  was 
subjected to chromatofocusing. The column was washed with 300 ml of 0.02  M 
acetate  buffer, and  eluted  with  linear  gradient  of acetate  buffer.  The peak of 
cofactor activity for I-dependent C3b or C3MA cleavage eluted from this column 
between the two major protein peaks (Fig.  1). 
The fractions with cofactor activity were pooled and dialyzed against  10 mM 
Tris-HCl overnight at 4°C. The dialyzed sample was then applied to the hydrox- 
ylapatite  column.  The  column  was  washed  with  the  equilibration  buffer  and 842 SEYA  ET  AL.  843 
eluted  with  15  mM  phosphate  buffer.  ~300  mi  of eluate  was  pooled  from 
fractions containing >80% of the initial cofactor activity and 20 mg of protein. 
This material was applied to a column of C3MA conjugated to Sepharose-6 B, (50 
mi, 4 mg of C3MA per milliliter of Sepharose). The column had been equilibrated 
with 10 mM phosphate buffer. Under these conditions, the cofactor activity was 
completely and reproducibly bound to this column. After being washed with 20 
mM phosphate buffer, the column was eluted with 0.5  M  NaCl.  -60%  of the 
initial cofactor activity was present, and  100 #g of protein were obtained. The 
fractions having the cofactor activity were pooled and dialyzed against 20 mM 
NaCI plus 20 mM phosphate buffer. The sample was applied to a Mono Q HPLC 
column (Pharmacia Fine Chemicals, Piscataway, NJ) (Fig.  2a) using an HPLC 
system (Millipore, Bedford, MA). The column was eluted with a linear (20-500 
mM) NaC1 gradient. Cofactor activity eluted between 140 and 220 mM. These 
fractions were radiolabeled and analyzed by SDS-PAGE (Fig. 2b). The cofactor 
activity is composed of several species, some of which can be separated in this 
step. The four to six fractions with cofactor activity contained 20 #g of protein 
and 60% of the cofactor activity of the initially solubilized material, representing 
a  163,000-fold purification. 
The fractions eluted from the Mono Q column (Fig. 2 b) with cofactor activity 
were of similar Mr (45,000-70,000) to that previously described for gp45-70 of 
U937 (arrows in Fig. 2 b; see also Fig. 4 and Cole et al. [9]). Therefore, although 
it  is  most  likely that  the protein  of Mr  45,000-70,000  is responsible  for the 
cofactor activity, labeled bands at the top of the gel and at an Mr of ~20,000 are 
present in some fractions. The material at the top of the gel is usually observed 
in the  late-eluting fractions,  but its presence does not correlate with cofactor 
activity.  Likewise,  the  band  at  Mr  ~20,000  is  only  observed in  some of the 
preparations (for example, it is not present in the column eluates shown in Fig. 
3a),  and again,  even when it is  present there is  no correlation with cofactor 
activity. The  apparent  extension of the  major  band  to  below Mr  45,000  in 
fraction d was not observed in other purifications (see below and Fig. 3). 
To further evaluate this protein, it was isolated by the same procedure from 
two additional sources of U937.  Interestingly, the cofactor protein from each 
source of U937 showed similar but not identical Mr and the relative quantity of 
FtGtlRE  2.  Elution profile of the Mono Q  HPLC column. The eluate of C3~A-Sepharose was 
dialyzed (Table I) and applied to the Mono Q  column (A, bottom).  An open arrow indicates 
the pass through fractions and a solid arrow represents the wash fraction. Percent cleavage of 
DACM-C3MA was determined (A, top) by SDS-PAGE (10% aerylamide) as described in Fig. 1. 
Each fraction (30 #1) obtained from the Mono Q  column was assessed for cofactor activity. 
The fractions possessing such activity are labeled a-j. 50 ttl of the fractions a-i were labeled 
by ~5I using the Iodogen method. The samples were subjected to SDS-PAGE (10% acrylamide) 
(B, top), and after drying the gel was exposed at -70°C for 2 h. Solid arrow, upper band of 
surface-labeled gp45-70;  open arrow,  lower band of surface-labeled gp45-70.  Bio-Rad Mr 
markers were used as standards. The identity of the labeled material at <30,000 Mr in lanesf 
and g is unknown (See Fig. 3 and Results). Also, a  variable amount of counts were observed 
at the top of the gel in lanesfand g. 50 #l of the column fractions (a-i) were incubated for 5 
h at 37°C with 1 #g of I and  I0 #g of DACM-C3MA (B, bottom).  Aliquots were reduced and 
analyzed by  SDS-PAGE (10%  acrylamide),  a2  bands with Mr of 43,000  and 46,000  were 
present and are similar in Mr to what others (4-6, 8) have reported for the first cleavage of 
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FIGURE 3.  Mono Q column elution profile of cofactor protein from two additional  strains of 
U937.  50 el of the fractions  encompassing  the area  of cofactor activity  were labeled  and 
subjected  to SDS-PAGE as per Fig. 2b (A and B, top). The position of surface-labeled  gp45- 
70 is marked by solid arrow (upper band) and open arrow (lower band).  Fraction  number is 
indicated alphabetically,  and these fractions are the same as those in Fig. 2.50 ttl (A,  bottom) 
or 100 ttl (B, bottom) of the column fractions  were incubated  for 5 h at 37°C with 1/zg ofI n 
10 ttg of DACM-C3M^. The aliquots were analyzed by slab (A), as described  in Fig. 2b, or rod 
(B) SDS-PAGE (10% acrylamide). In B, cofactor activity was estimated by fluorescent  intensity 
of al-fragment. 
the major Mr components varied (Fig. 3, a  and b). The Mr of the cofactor protein 
in Fig.  3a was higher (50,000-85,000)  than that of the usual gp45-70  of U937. 
However, the  labeled  proteins  seen  in  Figs.  2 b and 3 a  and b were eluted in the 
same  fractions  of  the  Mono  Q  column  and  showed  a  cofactor  activity  that 
correlated with the quantity of labeled protein with an Mr of 50,000-85,000.  In 
the experiment  shown in Fig,  3 a,  cofactor activity is present in fractions that do 
not contain the contaminating proteins.  In the experiment  of Fig.  3 b, a  correla- 
tion is seen  between  protein at ~70,000  Mr and cofactor activity (i.e,  prominent 
cofactor activity  in  tracks  d  and  e  but  not  in f,  which  has  the  labeled  band  at SEYA  ET  AL.  845 
-20,000).  These  elution  profiles  of the  cofactor protein  from  the  Mono  Q 
column always showed a tendency for the cofactor protein with the slower Mr to 
elute earlier than the faster-migrating proteins. The main peak of the cofactor 
protein is reproducibly observed between fractions c and g (160 mM to 200 mM 
NaCt concentration). As noted, fraction f usually contains larger (Mr -450,000) 
and smaller (Mr ~20,000) proteins. 
Comparative Analysis of Cofactor Protein Pur~ed  from U937 and gp45-70 Isolated 
from Surface-labeled U937.  The above purification procedure allowed the isola- 
tion of a protein with cofactor activity with an Mr similar to gp45-70, a membrane 
protein of U937 that binds C3b and C3(HeO) (9,  11).  To further compare this 
protein to gp45-70,  U937 cells were surface-labeled and solubilized (9). gp45- 
70 was isolated by C3(HeO) affinity chromatography and the eluate was evaluated 
on SDS-PAGE.  Purified cofactor protein from the same strain was electropho- 
resed on the same gel (Fig.  4a).  The stained cofactor protein shows a  similar 
mobility and a broad two band pattern with a predominant upper band in SDS- 
PAGE as the labeled gp45-70.  Also, note that this protein-stained material is 
derived from fraction g of Fig. 2b, and that the radiolabeled bands (Fig. 2b) and 
protein bands (track a, Fig. 4a) are the same. Multiple such comparisons have 
indicated that the bands defined by radiolabeling the column fractions identified 
the same proteins in approximately the same concentrations as those visualized 
by protein staining. 
Under reducing conditions, each subcomponent of the cofactor protein, like 
gp45-70  (9),  shifts (-8,000  increase in Mr)  to an  upper position  (not shown), 
suggesting that the cofactor protein is composed of a  single polypeptide chain 
containing intrachain disulfide bridges. 
Isolation of Cofactor Protein from Another Cell Line and Comparison to gp45-70 
of Its Surface-labeled Material.  A  second cell line was evaluated to determine 
whether the purification procedure would lead to the isolation of a protein with 
cofactor activity  which  aligned  with  gp45-70  (purified  from  surface-labeled 
material by affinity chromatography). On the T-cell line, HSB-2, gp45-70  is a 
single broad band with a  mean Mr of 62,000  (9).  The purification (exactly as 
that for U937) of a protein with cofactor activity was performed on two occasions, 
and a cofactor protein with the same binding and elution characteristics as the 
cofactor protein of U937 was isolated. The purified cofactor protein of HSB-2 
was compared to gp45-70 of surface-labeled HSB-2 that was isolated by affinity 
chromatography (Fig.  4b).  The cofactor protein aligned with gp45-70  under 
nonreducing and reducing (not shown) conditions, and the protein-stained band 
was predominantly a single band with a mean My of 62,000. These results, taken 
together with those for U937, indicate that for these two cells lines, the purified 
cofactor protein and gp45-70 have the same Mr. 
Another example of a protein stain of the purified cofactor protein is shown 
in Fig. 4c. In this figure, 2 or 4 #g of cofaetor protein (derived from HSB-2), H, 
and  C4bp  are  compared  on  one  gel.  While  at  4  #g,  all  three  complement 
regulatory proteins are easily visualized, at 2 #g, cofactor protein is not seen, but 
C4bp and H  are clearly visible.  The result is in part secondary to the fact that 
gp45-70 is a broader band than C4bp or H. However, in multiple such compar- 846  MEMBRANE  PROTEIN  WITH  COFACTOR  ACTIVITY SEYA  ET  AL.  847 
isons it appears that this protein is also not as efficiently stained by Coomassie R 
as C4bp, H, or marker proteins (32). 
Further Evaluation  of Cofactor Activity.  The purpose of these experiments was 
to evaluate the cofactor activity of the purified protein for I-mediated C3MA and 
C4MA cleavage (Figs.  5-7), and to compare the activity of the various fractions 
eluting from the Mono Q column. C3MA and C4MA were incubated with fractions 
of the purified cofactor protein and I. H and C4bp were used as positive controls 
in  the C3Ma and  the C4Ma cleavage studies,  respectively. The C3Ma cleavage 
products produced by cofactor protein plus I were identical in Mr to those of H 
plus  I;  that  is,  a  chain of C3MA was cleaved into  al  (Mr 75,000)  and a2  (Mr 
46,000 and 43,000) (4).  In the absence of I, cofactor protein had no proteolytic 
activity toward C3Ma or C4MA. Also, the two (early- vs. late-eluting) fractions had 
similar specific activities. 
The protein of U937 also serves as factor for the I-mediated cleavage of the 
a  chain of C4MA (Fig. 6, left) but required a higher concentration. The cleavage 
product of the a  chain was located between the trace amount of the a'  chain 
and the/3 chain. The fluorescent electrophoretogram shows that this cleavage 
product was derived from the a  chain (Fig. 6, right).  Based on these data, and 
judging from Mr, the product yielded by I plus cofactor protein is iC4Ma, first 
described by Nagasawa et al.  (24).  Higher concentrations of C4bp yielded C4c 
and C4d, while cofactor protein produced only trace amounts, even with a six- 
fold increase in cofactor protein and excess I (Fig. 6, middle). 
Fig. 5 suggests that the cofactor protein is a more efficient cofactor than H. 
Further experiments in which cofactor protein and H (Fig. 7) or cofactor protein 
and C4bp (not shown) were compared indicate that on a weight basis,  cofactor 
protein is ~50 times more effective than H  in the case of the first cleavage of 
C3Ma, while it is slightly weaker than C4bp in the case of the first cleavage of 
C4Ma. Cofactor protein is not able to efficiently mediate the second cleavage of 
fluid-phase iC3MA (Fig. 5) or iC4Ma (Fig. 6, middle). 
In other experiments (designed as per Figs. 5 and 7), the cofactor activity of 
various fractions eluting from the Mono Q  column was compared (not shown). 
The activity correlated with the quantity of protein eluting between 50,000 and 
FIGURE 4.  Comparison by SDS-PAGE of cofactor protein (MCP) and gp45-70. Using U937 
(A),  500 ng of fraction g (Fig. 2b) was electrophoresed (track a) together with the eluate of 
an iC3 affinity column purification of 125I surface labeled U937  (track b).  The gel was first 
stained by Coomassie R followed by silver staining. The lane containing gp45-70 was cut out 
and the autoradiogram  (b)  obtained as described in Materials and  Methods. Open arrow in 
autoradiogram (b), CR 1  ; closed arrows, gp45-70; open arrow in silver-stained gel (a), cofactor 
protein. The identity of the stained material at the top of gel in track a is unknown but does 
correspond to labeled material in Fig. 2 b, fraction g. In multiple similar comparisons, the same 
bands were identified by radiolabeling or protein staining of column fractions. Using HSB-2 
(B),  500 ng of purified cofactor protein was added to lane c (open arrow). An autoradiograph 
of the eluate of an iC3 affinity column purification of surface-labeled of HSB-2 is in track d 
(gp45-70  marked by filled arrow).  The experimental procedure was  identical to that of A. 
The lighter bands with Mr of 45,000  or less are usually not present (9) and their identity is 
unknown. Comparison of the cofactor protein of HSB-2 with C4bp and H (C). 2 ~g of purified 
cofactor protein (a), H  (b),  and C4bp (c), and 4 #g of cofactor protein (d),  H  (e), and C4bp 
(D, were mixed with 30% 2-ME and subjected to SDS-PAGE (10% acrylamide). The gels were 
stained by Coomassie R. Filled arrow, H; open arrow, C4bp; brackets, cofactor protein. 848  MEMBRANE  PROTEIN  WITH  COFACTOR  ACTIVITY 
FIGURE 5.  Cofactor activity for I-mediated cleavage of C3MA. Samples containing cofactor 
protein were dialyzed against PBS, pH 7.2, with 0.05% NP-40. C3MA (10 #g) was mixed with 
(a)  1 #g of I, (b) 10 #g of H, (c) 1 #g of I and 10 #g of H, (d)  1 #g of I and 200 ng of upper 
part of cofactor protein (MCP-U) (fraction d  of Fig.  3A), and (e)  1 #g of I  and 200  ng of 
middle and lower parts of cofactor protein (MCP-M+L) (fraction g of Fig.  2). The mixtures 
were incubated for 3 h at 37°C.  40 #l of a solution containing 10% SDS and 30% 2-ME was 
added, and the samples subjected to SDS-PAGE (10% acrylamide) and stained by Coomassie 
R. H, a  chain of C3, fl chain of C3, and the cleavage products derived from the first cleavage 
of the a  chain are marked. 
80,000  Mr,  and  thus,  despite  variability  in  Mr  and  charge,  no  differences  in 
specific activity were detected among the fractions.  These results are in accord 
with the data  shown in Figs.  2,  3, and  5,  in which the specific activity of each 
fraction  was similar.  Also, the specific activity of the cofactor protein of U937 
and HSB-2 was similar (not shown). 
Effect  of Cofactor  Protein  on  Decay of Alternative  and  Classical  C3  Conver- 
tases.  Dialyzed samples of cofactor protein, pretreated with 2 mM PMSF, 5 mM 
EDTA, and 5 mM IAA and adjusted to 200 ng per 100 tA, were mixed with the 
alternative  pathway complement  components and  NiCI~.  Cofactor protein  was 
not  a  decay accelerator  of the  alternative  pathway,  but  rather  behaved  as  a 
modest C3  convertase potentiator  (Fig.  8a).  Although  under  these conditions 
this effect was reproducible,  higher  concentrations  of cofactor protein did  not 
produce increasing stability of the convertase. Cofactor protein or an equivalent 
amount of C4bp was mixed with the classical pathway components and MgCI2. 
Cofactor protein did not accelerate the decay of the classical C3 convertase while 
C4bp was an efficient decay accelerator (Fig. 8 b). SEYA  ET  AL.  849 
FIGURE 6.  Cofactor activity for I-mediated C4uA cleavage. Samples were dialyzed as for Fig. 
5.  (Left) DACM-C4MA (20 #g) was mixed with (a)  1 #g of I, (b) 400 ng of C4bp, (c) 1 #g of I 
and 400 ng of C4bp, (d)  1 t~g of 1 and 400 ng of cofactor protein (MCP) upper part (fraction 
d  of Fig.  3A), and (e)  1 #g of I  and  400  ng of middle and lower parts of cofactor protein 
(fraction g of Fig. 2).  The mixtures were incubated  for 6  h  at  37°C and subjected to SDS- 
PAGE (10% acrylamide) under reducing conditions. Lanes a-e were stained by Coomassie R. 
Before staining, the gel was observed (right) under UV illumination (365 nm). The fluorescent 
electrophoretogram (lanes a'-e'  correspond to a-e of the left panel) is shown. The solid arrow 
points to a-N, the amino-terminal fragment of the a chain of C4MA. DACM-C4uA (20 #g) were 
mixed with (f) 3 t~g of 1 and 2.4 ug of cofactor protein (fraction f in Fig. 2) or (g) 3 #g of I 
and 5 t~g of C4bp. The mixtures were incubated for 6 h at 37 °C and subjected to SDS-PAGE 
(10% acrylamide). The gel was stained with Coomassie R. 
Discussion 
The  goal  of this  study  was  to  purify  gp45-70  in  quantities  sufficient for 
functional analysis. Because of the lack of an antibody to this protein, its biologic 
characteristics, including an acidic pI, C3b-ligand specificity, and pattern and Mr 
on  SDS-PAGE were used  in  devising a  purification procedure.  However, the 
most important biologic characteristic, which was central to the success of this 
endeavor, were our preliminary experiments suggesting that gp45-70 of U937 
cells possessed cofactor activity (16, 33). 
The initial step in the procedure, low ionic strength precipitation under acidic 
conditions,  was  based  on  the  knowledge that  gp45-70  had  an  acidic pI  and 
therefore would probably not be denatured by such treatment. The first column 
(chromatofocusing) also took advantage of the acidic pI of the molecule. In this 
step, the protein was also separated from CR 1, since this membane glycoprotein 
has  a  p!  of ~7.0  (22).  The  C3(H20)  affinity step  was  based  on  the  ligand 850  MEMBRANE  PROTEIN  WITH  COFACTOR  ACTIVITY 
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FIGURE  7.  Comparison of the cofactor activity of MCP to that of H. Variable amounts of H 
and MCP were mixed with radiolabeled DACM-C3M^ (18 #g) and I (1.2 #g) at a final volume 
of 200 #1 and incubated for 3 h at 37°C under the same conditions as noted in Materials and 
Methods. Reaction was stopped by adding 10 #1 of 10% SDS and 30% 2-ME, and the mixture 
was  then  subjected  to  SDS-PAGE.  Percent  cleavage was  determined  by  counting  the  gel 
fragments  corresponding  to  the  a2  band.  The  counts  in  the  gel band  containing the  ct2 
fragment generated in the presence of excess I and H was used as the 100% value (22). 
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FIGURE 8.  Effect of cofactor protein on convertase activity. Alternative pathway C3 conver- 
tase (a). The samples, containing constant amounts of C3(H~O), B, C3 and NiCI~, were mixed 
with 200 ng of H, 200 ng of the upper part of cofactor protein (MCP-U) (fraction d  of Fig. 
3a),  200 ng of middle and lower parts of cofactor protein (MCP-M+L) (fraction g of Fig. 2) 
or PBS,  pH  7.2,  with  0.05%  NP-40  (C,  control).  After adding  D,  generation  of C3a  was 
determined at timed intervals (22).  Classical pathway C3 convertase (b). The samples, contain- 
ing constant accounts of C4, C2, C3, and MgCI~, were mixed with 200 ng of C4bp, 200 ug of 
upper part of cofactor protein (MCP) (fraction d of Fig. 3 a), 200 ng of middle and lower parts 
of cofactor protein  (MCP) (fraction  g  of Fig.  2) and  PBS,  pH  7.2,  with  0.05%  NP-40  (C, 
control). After adding CIs, C3a generated was determined as for Fig. 7. 
specificity of gp45-70  of U937 (9). The Mono Q  column provided an efficient 
means for concentrating the protein, separation of the major species comprising 
the  protein,  and  removal  of a  variable  quantity  of minor  contaminants.  We 
routinely obtained ~30/~g of cofactor protein from 3  ×  10 ~° U937  or HSB-2 
cells and, based on the percent recovery, this calculates to a  mean of ~10,000 
molecules/cell. 
Having isolated a protein possessing cofactor activity, we then addressed several 
questions: (a) Utility of this approach in isolating a protein with cofactor activity 
from other cell lines.  (b) The relationship of the purified cofactor protein to 
gp45-70.  (c) The function of this protein,  especially in comparison to that of SEYA ET AL.  851 
the previously identified complement proteins with regulatory activity for the 
C3 convertases. 
In regard to the first question, the same procedure (elution profiles from each 
column were nearly identical) led to the purification of a protein with cofactor 
activity from two additional sources of U937 and from HSB-2. The relationship 
of the cofactor protein to gp45-70  was initially addressed by comparing their 
M~. For U937, this comparison was complicated by the variability in Mr of gp45- 
70 on this cell line. Depending on the source of the U937, the cofactor protein 
purified from U937  had a  slightly different Mr.  However, from a  given strain 
the surface labeled gp45-70 and the cofactor protein aligned by SDS-PAGE. To 
further address this second question, cofactor protein and gp45-70  of HSB-2 
were compared. This cell line has a  single band pattern for gp45-70  (9).  The 
cofactor protein was also a single band and aligned with gp45-70. 
The preceding Mr analysis combined with the very acidic pI of both molecules 
and their ligand binding specificity indicate that gp45-70 and cofactor protein 
are  identical  molecules.  Further  evidence  in  support  of this  conclusion  has 
recently been obtained in our laboratory by demonstrating that the carbohydrate 
composition of gp45-70  (11) and cofactor protein (our unpublished data) are 
similar.  Also,  for reasons that are yet to  be determined, gp45-70  is  variably 
glycosylated, and differences in sugar composition largely account for the cell- 
specific as well as the strain-specific (U937) variation in Mr (9,  11). 
The protein isolated from U937  and HSB-2 was a  cofactor for the first but 
not the second cleavage of C3b and C4b.  It is a  remarkable cofactor for C3b 
cleavage, being -50 times more efficient than H, which had been reported (22) 
to be the most potent cofactor for C3b cleavage. In the case of C4b, the activity 
for the first cleavage was  less  than  that  for equal  quantities  of C4bp.  These 
results are in accord with previous studies of gp45-70  indicating that it bound 
iC4 or C4b but with a lower affinity than C3(H20) (9, 16). C4bp is also a cofactor 
for the I-mediated first but not second cleavage of C3b (8, 26), and has a lower 
efficiency than  H  (4,  8).  Based on  these data,  the natural  ligand of cofactor 
protein is probably C3b. 
To allow a  functional comparison of the species with different Mr (50,000- 
85,000),  we  purposely  did  not  pool  the  fractions  eluting from  the  Mono Q 
column.  The  cofactor protein  isolated  from  U937  cells  consisted  of several 
species within this Mr range. In addition to their charge differences, the earlier 
eluting bands had a  higher Mr than the later eluting species. No differences in 
specific activity were detected among the fractions or between cofactor protein 
of U937  and  HSB-2.  Also, none of the fractions possessed decay-accelerating 
activity. With these comparative data in hand, the various fractions can now be 
pooled and the protein further purified and characterized. 
The activity profile of this cofactor protein is summarized and compared to 
the other regulatory proteins in Table II. Interestingly, the activity of cofactor 
protein is complementary to those of DAF (7, 34) (Table II). DAF lacks cofactor 
activity but decays both C3 convertases (7, 35), while the protein characterized 
in this report has cofactor activity but no decay-accelerating activity. We suspect 
that the reason these two proteins are widely distributed on human peripheral 
blood  cells  relates  to  their  synergistic activity  profile  such  that  complement 852  MEMBRANE  PROTEIN  WITH  COFACTOR  ACTIVITY 
TABLE  II 
Comparison of Activity Profile of  Membrane Cofactor Protein to that of Other Complement 
Regulatory Proteins 
Activity 
Membrane associated  Fluid phase 
CR 1  DAF  MCP  H  C4bp 
C3b binding  +  -*  + 
Cofactor for first cleavage of C3b  +  -  + 
CotZactor  for second cleavage of C3b  +  -  - 
Alternative complement pathway decay  +  +  - 
C4b binding  +  -*  + 
Col~actor  for first cleavage of C4b  +  -  + 
Cofactor for second cleavage of C4b  +  -  - 
Classical complement pathway decay  +  +  - 
Rosette formation  +  -  -* 
+  + 
+  + 
4-:~ 
+ 
-  + 
±*  + 
-  + 
* Unpublished data. 
~; Relatively inefficient at promoting this cleavage. 
activation on autologous tissue is inhibited. An important question, the relative 
intrinsic (cofactor activity for C3b on the same cell) vs. extrinsic (cofactor activity 
for C3b bound to other cells or to soluble and particulate immune complexes) 
activity of this regulatory protein remains to be determined. 
A purification procedure has been devised that permits isolation in reasonable 
yields and purity of an additional cell-associated complement regulatory protein. 
The structure of this protein indicates that it is identical to a previously identified 
C3b-binding membrane protein of human PBL, platelets, and cell lines, termed 
gp45-70  (9,  10).  The  functional studies reported herein  indicate  that  it  has 
strong cofactor activity for the I-mediated first cleavage of C3b,  but no decay- 
accelerating activity. Based on these results, we suggest that gp45-70 be renamed 
membrane cofactor protein (MCP).  The activity profile of MCP is unique for 
the  regulatory proteins,  whose activity is  directed at  the C3  convertases and 
suggests an  important  role for MCP  in  controlling complement activation on 
autologous tissue. 
Summary 
Based on preliminary evidence indicating that a cell-associated protein of U937 
(a  human monocyte-like cell  line) possessed cofactor activity and was not  the 
C3b/C4b receptor, we sought to further characterize this protein. A sequential 
four-column purification procedure was devised that includes C3(H20) affinity 
chromatography to isolate in reasonable yields and purity a cell-associated protein 
of U937 and several other human cell lines. Based on its pattern and Mr on SDS- 
PAGE, acidic pI,  and  ligand specificity, it  is  identical to a  recently described 
C3(H20) or C3b-binding membrane glycoprotein of human PBL and cell lines; 
having no presently identified function, it was termed gp45-70. After purifying 
this protein, we determined its functional capabilities and compared them to those 
of the other complement proteins with regulatory activity directed at components 
comprising the C3 convertases. This protein was the most efficient (50 times that 
of H) yet-described cofactor for the I-mediated first cleavage of C3b. It also was SEYA ET  AL.  853 
a  cofactor for the first cleavage of C4b,  but was not as efficient as C4bp.  The 
second cleavage of C3b and C4b was not efficiently mediated.  It had no ability 
to accelerate decay in the classical or alternative pathway C3 convertases. Based 
on this unique activity profile and ability to be surface labeled, we have renamed 
this molecule membrane cofactor protein (MCP).  We suggest that this protein 
plays a major role in preventing autologous complement activation. 
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comments. We also thank Mrs. L. Whiteley, Mrs. J. Weston, and Ms. P. Stewart for their 
excellent secretarial help. 
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